Literature DB >> 1683085

Increased soluble interleukin 2 receptor levels in autoimmune thyroid disease.

K Nakanishi1, Y Taniguchi, Y Ohta.   

Abstract

We measured soluble interleukin 2 receptor, a part of the Tac protein (p55), in peripheral blood to study the immunological condition of the T cell in autoimmune thyroid disease. In 26 patients with untreated Graves' disease and 7 hyperthyroid patients with Hashimoto's thyroiditis, the mean levels of soluble IL-2 receptor were both significantly higher than in normal controls (1497 +/- 649 (mean +/- SD), 641 +/- 137 vs 221 +/- 63 10(3) U/l, p less than 0.001). There was good correlation between soluble IL-2 receptor levels and blood thyroxine levels (r = 0.684, p less than 0.001) in patients with untreated Graves' disease, but no correlation of soluble IL-2 receptor with TSH-inhibitory immunoglobulins, TS-ab, thyroidal autoantibodies to thyroglobulin and thyroidal microsomal antigen was found. We thought that the level of soluble IL-2 receptor is not dependent only on immunological conditions, but also on thyroid hormone status. When T3 was administered to subjects in remission from Graves' disease and in normal controls, the soluble IL-2 receptor levels significantly increased. Moreover, the mean level of soluble IL-2 receptor in patients with toxic multinodular goitre was also significantly higher than in normal controls (411 +/- 148 vs 221 +/- 63 10(3)U/l, p less than 0.05). We conclude that the soluble IL-2 receptor levels are higher in sera of subjects with elevated levels of thyroid hormone.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683085     DOI: 10.1530/acta.0.1250253

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  6 in total

1.  Serum levels of interleukin-12 in Graves' disease and their dynamic changes after surgery.

Authors:  Saburo Murakami; Katsuhiko Okubo; Yoshitaka Tsuji; Hideto Sakata; Masataka Kikuchi; Takehiro Takahashi; Takaharu Kato; Renzo Hirayama
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

2.  Serum-soluble interleukin-2 receptor levels before and after surgical treatment for Graves' disease.

Authors:  S Murakami; A Kobayashi; K Kuma; H Murai; Y Okamura; A Satomi; K Ishida
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

3.  Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis.

Authors:  R C Smallridge; G C Tsokos; K D Burman; L Porter; T Cranston; P P Sfikakis; B L Solomon
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

4.  Serum soluble interleukin-2 receptors as an index of the biological activity of thyroid hormones in hyperthyroidism.

Authors:  E Koukkou; P Panayiotidis; N Thalassinos
Journal:  J Endocrinol Invest       Date:  1995-04       Impact factor: 4.256

5.  Serum soluble interleukin 2 (IL-2) receptor (sIL-2R) in differentiated thyroid carcinoma.

Authors:  S Mariotti; G Barbesino; P Caturegli; M Marinò; L Manetti; L Fugazzola; F Pacini; A Pinchera
Journal:  J Endocrinol Invest       Date:  1994-12       Impact factor: 4.256

6.  Epitope blocking: positive and negative effects on the biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment of two antibodies against different epitopes of the circulating antigen.

Authors:  H Kobayashi; B F Sun; E S Han; M K Kim; N Le; Q C Wang; D L Nelson; I Pastan; T A Waldmann; C H Paik; J A Carrasquillo
Journal:  Jpn J Cancer Res       Date:  1998-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.